Daewoong Pharma reports 104 patients enrolled in Phase 2 IPF trial of Bersiporocin
Bitget2026/09/24 07:01- Daewoong Pharma presented baseline data for 104 patients in a global Phase 2 trial of IPF candidate bersiporocin at ERS 2026.
- The study is designed to test the drug in patients already on standard antifibrotic therapy, as well as those not receiving it.
- Enrollment is complete in the US and South Korea, positioning the program for a key efficacy and safety readout.
- Top-line Phase 2 results are expected in H1 2027, a near-term catalyst for the asset’s next-stage development plans.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. Stock Market Moves | GameStop rises 1.4% pre-market as CEO buys back shares
The market awaits PCE, US stock index futures rise, 10-year US Treasury yield edges down, Brent crude drops 1%, gold stands above 4200.
Dow Jones futures rose 0.5%, S&P 500 futures increased by 0.3%, and Nasdaq 100 futures were up 0.2%. The yield on the 10-year U.S. Treasury note edged down slightly to 5.21%. Brent crude oil fell 1.0% during the day to $95.18 per barrel. Spot gold climbed above $4,200 per ounce, rising 0.44% on the day.
Update 2 - UK Greggs raises profit forecast but plans to close some factories
Crypto prices
More
